RCUS Stock Plunged: Here's What Happened

The Situation

Arcus Biosciences Inc (NYSE: RCUS) shares – a clinical-stage biopharmaceutical company developing and commercializing cancer therapies – plunged on Tuesday after data it shared data relevant to its lung cancer drug. As of 12:00 PM ET, Arcus shares are down by 31.76%.

The Explanation

Arcus Inc officially went public on Mar 14, 2018, reaching an all-time high of $48.47 on Nov 23, 2021. Overall, the stock is still up by 19.60%, although it is down by 49.68% year-to-date.

The company announced the result data for its cell lung cancer drug developed with Gilead Sciences Inc. with only 41% of patients responding to the treatment. The median showed patients could live for 12 months before cancer finally worsened; this also fell down compared to the 45% of patients responding by Roche.

See the $RCUS chart performance here.

The Effect

Arcus Inc shares dropped after the results of the lung cancer drug development could not beat the competition.  The investors' reaction happened as the company's lung drug results lagged behind by just 4% compared to its competitor.

Since investors can't know for sure whether the company will be able to increase the percentage response of patients, it is more important to focus on Arcus' business.

See full $RCUS flow at: https://unusualwhales.com/stock/RCUS/flow-overview

tastytrade logo+
Get the best broker for options trading and earn Unusual Whales discounted! in cash with an eligible account deposit at tastytrade. Get an Unusual Whales bonus when you deposit $2000. Offer expires 3/31/25. Certain restrictions, terms and conditions apply.
Unusual Whales does not confirm the information's truthfulness or accuracy of the associated references, data, and cannot verify any of the information. Any content on this site or related pages are not intended to provide legal, tax, investment or insurance advice. Unusual Whales Inc. is not registered as a securities broker-dealer or an investment adviser with the U.S. Securities and Exchange Commission, the Financial Industry Regulatory Authority (“FINRA”) or any state securities regulatory authority. Nothing on Unusual Whales should be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security by Unusual Whales or any third party. Options, investing, trading is risky, and losses are more expected than profits. Please do own research before investing. Please only subscribe after reading our full terms and understanding options and the market, and the inherent risks of trading. It is highly recommended not to trade on this, or any, information from Unusual Whales. Markets are risky, and you will likely lose some or all of your capital. Please check our terms for full details.
Any content on this site or related pages are not intended to provide legal, tax, investment or insurance advice. Unusual Whales Inc. is not registered as a securities broker-dealer or an investment adviser with the U.S. Securities and Exchange Commission, the Financial Industry Regulatory Authority (“FINRA”) or any state securities regulatory authority. Nothing on Unusual Whales should be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security by Unusual Whales or any third party. Certain investment planning tools available on Unusual Whales may provide general investment education based on your input. You are solely responsible for determining whether any investment, investment strategy, security or related transaction is appropriate for you based on your personal investment objectives, financial circumstances and risk tolerance. You should consult your legal or tax professional regarding your specific situation. See terms for more information.